RA
UTHR icon

Rise Advisors’s United Therapeutics UTHR Stock Holding History

Rise Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-97
Closed -$40.7K – 1363
2025
Q3 		$40.7K Buy
97
+2
+2% +$673 0.01% 300
2025
Q2 		$27.3K Hold
95
– – 0.01% 380
2025
Q1 		$29.3K Sell
95
-43
-31% -$14.7K 0.01% 333
2024
Q4 		$48.7K Hold
138
– – 0.02% 234
2024
Q3 		$49.5K Hold
138
– – 0.02% 245
2024
Q2 		$44K Hold
138
– – 0.02% 253
2024
Q1 		$31.7K Buy
+138
New +$31.1K 0.02% 361

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Rise Advisors's UTHR Position: Q4 2025 in Review

Rise Advisors sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 97 shares — an estimated $40.7K sold.

Rise Advisors first reported a position in UTHR in Q1 2024 and held it in 7 quarters. The position peaked at $49.5K in Q3 2024. 838 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

  • Rise Advisors reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 97 United Therapeutics shares in Q4 2025, an estimated $40.7K.
  • Rise Advisors first reported a position in United Therapeutics in Q1 2024 and held it in 7 quarters.
  • Rise Advisors's United Therapeutics position peaked at $49.5K in Q3 2024.
  • 838 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.